Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Musashi-2 protein regulates function, development of blood stem cells

Researchers at McMaster University's Stem Cell and Cancer Research Institute have made significant steps forward in understanding the stem cells of the human blood system after discovering how a key protein allows for better control and regeneration of these cells.

28 Apr 2016

Study on HDAC enzymes could lead to development of better drugs for treatment of cancer, Alzheimer’s

New knowledge about the mechanism of specific protein complexes in the body could help in the development of better drugs for the treatment of diseases such as cancer and Alzheimer’s, according to research led by the University of Leicester.

25 Apr 2016

Rab inhibition may be a promising antimyeloma strategy

Roswell Park Cancer Institute researchers are investigating agents that target and disrupt the trafficking of monoclonal antibodies in multiple myeloma, a cancer of the bone marrow. The results will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.

22 Apr 2016

BCR-ABL halving time indicates CML prognosis during front-line TKI

Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia patients undergoing first-line tyrosine kinase inhibitor therapy, say researchers.

21 Apr 2016

Novel combination of cancer drugs can have therapeutic impact on diffuse large B-cell lymphoma

New research from Roswell Park Cancer Institute shows that promising cancer drugs used in combination can have significant therapeutic impact on a particularly aggressive subtype of diffuse large B-cell lymphoma (DH-DLBCL) in preclinical studies. The researchers will present their findings at the American Association for Cancer Research (AACR) Annual Meeting 2016, to be held April 16-20 in New Orleans.

21 Apr 2016

Imatinib-related symptom burden linked to adherence in Indian CML patients

Research shows low adherence to imatinib in Indian patients with chronic myeloid leukaemia, with an association between nonadherence and worse symptom burden related to treatment.

21 Apr 2016

Intestinal bacteria can be used to reduce cancer risk, reveals UCLA study

Researchers have shown that various types of intestinal bacteria might be factors in both causing and preventing obesity, and in other conditions and diseases. Now, a UCLA study suggests that it could also potentially be used to reduce the risk for some types of cancer.

16 Apr 2016

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

13 Apr 2016

Alternative splicing regulates MALT1 protein to have stronger or weaker effect on immune system

The protein MALT1 is an important switch in immune cells and affects their activity. Researchers at Helmholtz Zentrum München report in 'Nature Communications' that this activation is not always equally strong. Through alternative splicing, two variants of the protein may arise which have a stronger or weaker effect on the immune system. Understanding this process is important for the pharmacological use of MALT1.

12 Apr 2016

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic lymphoma kinase (ALK) and have already received another treatment. In November 2015, the approval was extended to first-line treatment.

11 Apr 2016

Autologous haematopoietic stem cell transplantation promise for myasthenia gravis

Study findings in seven patients with severe myasthenia gravis support the use of autologous haematopoietic stem cell transplantation for achieving long-term remission.

7 Apr 2016

Inflectra (infliximab-dyyb) approved for multiple indications

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA.

6 Apr 2016

Plitidepsin in combination with dexamethasone shows top-line results in Phase III multiple myeloma trial

PharmaMar today announced positive top-line results of its Phase III clinical trial -ADMYRE- with Aplidin (plitidepsin) in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma (MM).

2 Apr 2016

MicroRNA controls tumor cell proliferation in most aggressive large B-cell lymphoma

A recent study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine showed that a microRNA called miR-181a dampens signals from the cancer-driving NFκB protein pathway in the most aggressive large B-cell lymphomas (DLBCL). By reducing NFκB signaling, miR-181a controls tumor cell proliferation and survival and could be the target of novel therapies. The study was published in the journal Blood.

2 Apr 2016

Scientists develop mouse model to gain new insights into genetic mechanisms underlying AML

A novel mouse model of a highly lethal form of acute myeloid leukemia (AML) offers a new tool for scientists working to better understand this disease and research new therapeutic targets.

31 Mar 2016

Mutations in cancerous lymphoma cells break through four protein locks

Protein chemists at Johns Hopkins report they are closer to explaining why certain blood cancers are able to crack a molecular security system and run rampant.

22 Mar 2016

Metabolite in gut microbiome could improve outcomes after bone marrow transplant

Could playing better defense make bone marrow transplants more successful? With this question in mind, researchers began looking at whether the trillions of little bugs and bacteria living in our gastrointestinal tract could be the key to playing defense.

22 Mar 2016

Novel compound shows promise as potential treatment for acute myeloid leukemia

A novel compound has shown promise in preclinical studies as a treatment for acute myeloid leukemia, more than doubling median days of survival even in a drug-resistant form of the disease.

21 Mar 2016

Genomic profiling could help provide targeted therapies for difficult to treat cancer tumors

Research from Rutgers Cancer Institute of New Jersey examining difficult to treat cancer tumors through genomic profiling shows that tumors with alterations in a signaling pathway responsible for cell regulation may respond to targeted therapy regardless of where the tumor originated in the body.

18 Mar 2016

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin's lymphoma than the general population, study findings indicate.

17 Mar 2016

Lymphoma News and Research

Further Reading

Musashi-2 protein regulates function, development of blood stem cells

Study on HDAC enzymes could lead to development of better drugs for treatment of cancer, Alzheimer’s

Rab inhibition may be a promising antimyeloma strategy

BCR-ABL halving time indicates CML prognosis during front-line TKI

Novel combination of cancer drugs can have therapeutic impact on diffuse large B-cell lymphoma

Imatinib-related symptom burden linked to adherence in Indian CML patients

Intestinal bacteria can be used to reduce cancer risk, reveals UCLA study

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

Alternative splicing regulates MALT1 protein to have stronger or weaker effect on immune system

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

Autologous haematopoietic stem cell transplantation promise for myasthenia gravis

Inflectra (infliximab-dyyb) approved for multiple indications

Plitidepsin in combination with dexamethasone shows top-line results in Phase III multiple myeloma trial

MicroRNA controls tumor cell proliferation in most aggressive large B-cell lymphoma

Scientists develop mouse model to gain new insights into genetic mechanisms underlying AML

Mutations in cancerous lymphoma cells break through four protein locks

Metabolite in gut microbiome could improve outcomes after bone marrow transplant

Novel compound shows promise as potential treatment for acute myeloid leukemia

Genomic profiling could help provide targeted therapies for difficult to treat cancer tumors

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News